07/07/2026 Vera Therapeutics announced US FDA accelerated approval of TRUTAKNA™ for adults with primary IgA nephropathy Turn Therapeutics announced the final stage 2 design and data-driven expansion of the GX-03 phase 2 trial in Atopic Dermatitis Everest Medicines announced the closing of its exclusive licencing agreement with Travere Therapeutics for civorebrutinib Vera Therapeutics announced US FDA accelerated approval of TRUTAKNA™ for adults with primary IgA nephropathy (R

13/02/2026 Novartis announced Phase 3 data in adult patients with IgA nephropathy Novartis announced Phase 3 data in adult patients with IgA nephropathy ( Ref ) Novartis announced final results from its Phase 3 ALIGN/ NCT04573478 study which evaluated Vanrafia (atrasentan; an ETA receptor antagonist) in adult patients with IgA nephropathy (IgAN) The study demonstrated a slowing of kidney function decline in adult patients with IgAN The ALIGN study showed a difference of 2.39